ARTICLE | Product Development

COVID-19 pipeline: spotlight on strategies to block viral entry or replication

May 15, 2020 9:01 PM UTC

Therapies that directly block entry of SARS-CoV-2 or its replication in host cells are a major focus of the COVID-19 pipeline, representing over one third of all therapeutics programs.

Should the first vaccines making their way through the clinic fail to prevent COVID-19, these compounds will represent the next, best hope for taming the disease. The entire pipeline, including vaccines and therapies, has swollen to at least 426 programs, according to BioCentury’s COVID-19 Resource Center. ...